1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6F67E719F00B5E19285257DC600674094
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/patient-support-excellence-program-activities-and-alliances?opendocument
18
19opendocument
2054.82.99.169
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Marketing Management Patient Advocacy

Patient Support Excellence: Program Activities and Alliances

ID: 5345


Features:

16 Info Graphics

10 Data Graphics

100+ Metrics

2 Narratives


Pages/Slides: 34


Published: 2015


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Patient Support Excellence: Program Activities and Alliances"



Study Overview

Throughout the pharmaceutical sector, organizations are instilling a patient-centric approach across their operations, from medical to commercial. Facing a competitive marketplace and patient-outcomes focused payers and regulators, pharmaceutical companies are turning to patient support programs and activities to drive clinical and commercial success. As pharma has enhanced its patient programs, the industry is continually evaluating which programs and alliances are most effective for enhancing patient-centricity.


Best Practices, LLC conducted this study to generate reliable industry metrics on which patient programs companies are using and which they believe are most effective. The study also reviews issues around partnerships with patient advocacy groups, including advocacy group activities and funding. The research also presents participants' best practices and pitfalls around patient support programs. This benchmarking study will provide patient support leaders with metrics and insights they can use to assess their patient support activities and alliances.

This study has small, medium and large company segments on some questions


Key Topics

  • Patient Support in Pharma
  • Program Activities and Alliances
  • Best Practices and Pitfalls

Sample Key Metrics
  • Rate the effectiveness of activities used as part of your Patient Support program
  • Rate importance of patient advocacy group activities
  • Approach that works best to deploy advocacy group grants
  • Level of legal department involvement in patient support activities
  • Describe any involvement patient support group has with health outcomes data collection
  • Share three best practices associated with effective patient support
  • Share three pitfalls associated with patient support programs

Sample Key Finding
  • Patient Assistance Programs Seen as Linchpin of Patient Support Activities: Co-pay assistance programs were clearly seen as the most effective Patient Support activity, with 71% citing that activity as highly effective. While no other activity was singled out as highly effective by most, 77% said celebrity spokespersons were either not used or had low effectiveness.
  • Patient Advocacy Activities Seen as Important Part of Patient Program: 100% of respondents felt creating alliances with advocacy groups was either highly important (56%) or moderately important(44%).

Study Methodology

Nineteen Patient Support leaders from 19 different companies participated in this study. Participants were recruited because of their involvement in Patient Support programs.

Industries Profiled:
Health Care; Pharmaceutical; Biotech; Biopharmaceutical; Clinical Research; Laboratories; Medical Device; Chemical


Companies Profiled:
Sanofi; Merck; GlaxoSmithKline ; Novo Nordisk; Daiichi Sankyo; Pfizer; Boehringer Ingelheim; AstraZeneca; Astellas; Baxter Healthcare; EMD Serono; Merck Serono; Celgene; UCB Pharma; Millenium; Dr Reddy's Laboratories; Roche; LEO Pharma; Horizon Pharma


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.